Anti-FGF23 therapeutic antibody (Pre-made Burosumab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Burosumab (INN, sold under the brand name Crysvita) is a human monoclonal antibody medication for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia.[ Burosumab was approved by the FDA for its intended purpose, in patients aged one year and older, in April 2018.[8] The FDA approval fell under both the breakthrough therapy and orphan drug designations. It was approved for use in the European Union in February 2018.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-086-1mg	1mg	3090
GMP-Bios-ab-086-10mg	10mg	21890
GMP-Bios-ab-086-100mg	100mg	148000
GMP-Bios-ab-086-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Anti-FGF23 therapeutic antibody (Pre-made Burosumab biosimilar,Whole mAb)
INN Name	Burosumab
Target	FGF23
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Approved
Est. Status	Active
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	Kyowa Hakko Kirin;Ultragenyx Pharmaceutical
Conditions Approved	X-linked dominant hypophosphataemic rickets;Osteomalacia
Conditions Active	Nevus
Conditions Discontinued	na
Development Tech	na